Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway

Patent metadata

Field	Value
Publication number	US-12595278-B2
Application number	US-202318485699-A
Country	US
Kind code	B2
Filing date	Oct 12, 2023
Priority date	May 14, 2018
Publication date	Apr 7, 2026
Grant date	Apr 7, 2026

Abstract

Provided herein are biaryl amides and coumarin-based compounds with modified sugar groups having the formulas:

wherein variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.

First claim

What is claimed is:

1 . A method of treating diabetic peripheral neuropathy, in a patient in need thereof comprising administering to the patient in need thereof a therapeutically effective amount of a compound of the formula:

wherein:
n is 1;
Y 1 is -alkanediyl (C≤6) -, —C(O)-alkanediyl (C≤6) -, or a substituted version of any of these groups;
Y 2 is O;
R 3 is —NR 11 R 11 ′ or —C(O)NR 12 R 12 ′, wherein:
R 11 and R 11 ′ are each independently hydrogen, alkyl (C≤6) , substituted alkyl (C≤6) , acyl (C≤6) , or substituted acyl (C≤6) ;
R 12 and R 12 ′ are each independently hydrogen, alkyl (C≤6) , or substituted alkyl (C≤6) ;

R 7 is alkyl (C≤6) or a substituted alkyl (C≤6) ;
R 8 is hydroxy, alkoxy (C≤6) , or substituted alkoxy (C≤6) ; and
R 9 and R 10 are each hydroxy;

or a pharmaceutically acceptable salt of the formula.

2 . The method of claim 1 , wherein the patient is a mammal.

3 . The method of claim 2 , wherein the patient is human.

4 . The method of claim 1 , wherein the compound is further defined as:

wherein:
n is 1;
R 7 is alkyl (C≤6) or substituted alkyl (C≤6) ;
R 8 is hydroxy, alkoxy (C≤6) , or substituted alkoxy (C≤6) ; and
R 9 and R 10 are each hydroxy;

or a pharmaceutically acceptable salt thereof.

5 . The method of claim 4 , wherein the compound is further defined as:

wherein:
R 7 is alkyl (C≤6) , alkoxy (C≤6) ; and
R 8 is hydroxy alkoxy (C≤6) , or substituted version of any of these groups;

or a pharmaceutically acceptable salt thereof.

6 . The method of claim 4 , wherein the compound is further defined as:

wherein:
R 7 is alkyl (C≤6) , or substituted alkyl (C≤6) ;
R 8 is alkoxy (C≤6) or substituted alkoxy (C≤6) ;

or a pharmaceutically acceptable salt thereof.

7 . The method of claim 4 , wherein the compound is further defined as:

wherein:
R 7 is alkyl (C≤6) or substituted alkyl (C≤6) ;
R 8 is hydroxy;

or a pharmaceutically acceptable salt thereof.

8 . The method of claim 1 , wherein R 7 is alkyl (C≤6) .

9 . The method of claim 1 , wherein R 8 is hydroxy.

10 . The method of claim 1 , wherein R 8 is alkoxy (C≤6) or substituted alkoxy (C≤6) .

11 . The method of claim 1 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt of any of these formulas.

12 . The method of claim 11 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt of either formula.

13 . The method of claim 12 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt thereof.

14 . The method of claim 12 , wherein the compound is further defined as:

or a pharmaceutically acceptable salt thereof.

Assignees

• Reata Pharmaceuticals Inc

Inventors

• Jiang Xin
• Visnick Melean
• Bender Christopher F
• Bolton Gary
• CAPRATHE Bradley
• Lee Chitase

Classifications

• C07H1/00

  Processes for the preparation of sugar derivatives · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title